Annovis Bio (NYSE: ANVS) reported first-quarter 2026 business and financial results, highlighting continued advancement of its clinical-stage neurodegenerative disease programs. The company announced 85% enrollment in its pivotal Phase 3 Alzheimer’s disease trial and closure of enrollment to new participants after reaching sufficient screening levels to meet enrollment goals.
The company also reported progress in its Parkinson’s disease open-label extension study, which has reached 40% enrollment, alongside new biomarker initiatives and AI-powered digital monitoring, as Annovis continues advancing buntanetap toward potential regulatory submission.
Annovis Bio is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The 85% enrollment milestone in the Phase 3 Alzheimer’s trial is a significant step toward completing the study, which is designed to evaluate buntanetap’s efficacy in slowing or halting cognitive decline. The decision to close enrollment to new participants after achieving sufficient screening levels suggests that the company is on track to meet its target for statistical powering. For industry observers, this progress indicates that Annovis is moving closer to a potential regulatory submission, which could have substantial implications for the Alzheimer’s treatment landscape.
In the Parkinson’s disease program, the open-label extension study has reached 40% enrollment. This study is critical for assessing long-term safety and durability of effect. The company is also deploying new biomarker initiatives and AI-powered digital monitoring, which could enhance the ability to track disease progression and treatment response in real time. These digital tools may provide more granular data than traditional clinical assessments, potentially accelerating development timelines and improving trial efficiency.
For business leaders and technology executives, the integration of AI into clinical trials represents a broader trend toward digital health and precision medicine. Annovis’s use of AI-powered monitoring could serve as a model for other biotech firms seeking to streamline drug development and reduce costs. The implications for the industry are significant: if buntanetap proves successful, it could offer a new therapeutic option for millions of patients with Alzheimer’s and Parkinson’s diseases, potentially reshaping standard of care.
Annovis is headquartered in Malvern, Pennsylvania. More information about the company and its programs can be found at www.annovisbio.com. The full press release is available at https://ibn.fm/M77X4.
